{"url": "https://web.archive.org/web/20170406171016/http://www.prnewswire.com/news-releases/allergan-reports-topline-phase-ii-data-supporting-advancement-of-botox-onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-mdd-300435486.html", "text": "\"We are encouraged by these data and the potential impact on adults with major depressive disorder. Given our in-depth and extensive clinical trial experience in CNS including depression, we plan to move forward and develop a phase 3 program for a potential new treatment option for patients,\" said David Nicholson, Chief Research and Development Officer, Allergan.\n\nStudy Design\n\nThis study was a proof of concept Phase II, multi-center, randomized, double-blind, placebo-controlled, 2-dose cohort parallel group, single treatment study in adults females with moderate to severe Major Depressive Disorder (MDD). 258 patients (with a minimum total score of 18 on the Hamilton Rating Scale for Depression and a score of 4 on the Clinical Global Impressions Scale) were randomized (1:1:2) into three groups receiving either BOTOX\u00ae 30 U, BOTOX\u00ae 50 U or placebo. As the number of injections differed between the 30 U and the 50 U group, each study site was randomly assigned to only one of the doses and matching placebo. The study took place over 26 weeks with a 2 week screening period and up to 24 weeks post DB treatment. The primary endpoint of the study was change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score for BOTOX\u00ae 30 U vs. placebo and BOTOX\u00ae 50 U vs. placebo; and combined BOTOX\u00ae 30 U and 50 U vs. combined placebo groups.\n\nAbout Allergan\n\nAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.\n\nAllergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\n\nAllergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.\n\nOur Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.\n\nWith commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.\n\nFor more information, visit Allergan's website at www.Allergan.com.\n\nForward-Looking Statement\n\nStatements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the \"Actavis plc\" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.\n\nCONTACTS:\n\nInvestors:\n\nKarina Calzadilla\n\n(862) 261-7328\n\nMedia:\n\nMark Marmur\n\n(862) 261-7558\n\nTo view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-reports-topline-phase-ii-data-supporting-advancement-of-botox-onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-mdd-300435486.html\n\nSOURCE Allergan plc\n\nRelated Links\n\nhttp://www.allergan.com\n\n", "images": ["https://web.archive.org/web/20170406171016im_/http://prnewswirecom2.122.2o7.net/b/ss/prnewswirecom2/1/H.20.3--NS/0", "https://web.archive.org/web/20170406171016im_/http://www.prnewswire.com/news-releases/allergan-reports-topline-phase-ii-data-supporting-advancement-of-botox-onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-mdd-300435486.html", "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=facebook", "https://web.archive.org/web/20170406171016im_/http://content.prnewswire.com/designimages/logo_prn_mobile_no_pad.png", "https://web.archive.org/web/20170406171016im_/http://photos.prnewswire.com/prnvar/20150612/222796LOGO?max=700", "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=thumbnail", "https://web.archive.org/web/20170406171016im_/http://s.clickability.com/s?19=990&14=0&6=418422583&7=506122&25=0&18=0.11148329356054487", "https://web.archive.org/web/20170406171016im_/http://content.prnewswire.com/designimages/logo_prn_trans.png", "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?w=200"], "top_img": "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=facebook", "keywords": [], "authors": ["Allergan Plc"], "canonical_link": "https://web.archive.org/web/20170406171016/http://www.prnewswire.com/news-releases/allergan-reports-topline-phase-ii-data-supporting-advancement-of-botox-onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-mdd-300435486.html", "title": "Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX\u00ae (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)", "meta_data": {"msvalidate.01": "9D28F7743C790DD88F2D9C7375EF7ED5", "twitter": {"card": "summary", "site": "@PRNewswire", "image": "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=twitter"}, "viewport": "width=device-width, initial-scale=1", "og": {"title": "Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX\u00ae (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)", "type": "website", "description": "DUBLIN, April 5, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today...", "image": "https://web.archive.org/web/20170406171016im_/https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=facebook", "url": "https://web.archive.org/web/20170406171016/http://www.prnewswire.com/news-releases/allergan-reports-topline-phase-ii-data-supporting-advancement-of-botox-onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-mdd-300435486.html"}, "p": {"domain_verify": "7d052ac42aa9e7505635404745861994"}, "robots": "index, follow", "author": "Allergan plc", "keywords": "Allergan plc, NYSE:AGN, ireland, Clinical Trials & Medical Discoveries, Health Care & Hospitals, Biotechnology, Medical Pharmaceuticals, Pharmaceuticals", "description": "DUBLIN, April 5, 2017 /PRNewswire/ -- Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX\u00ae (onabotulinumtoxinA) for the Treatment of...", "cf_entity_title": "Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX\u00ae (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)", "cf_entity_thumbnail_url": "http://content.prnewswire.com/designimages/logo-prn-01_PRN.gif", "date": "2017-04-05T16:30:00Z", "Publisher": "PR Newswire", "geo.placename": "DUBLIN, April 5", "geo.region": "ireland"}, "movies": [], "publish_date": null, "source": "https://web.archive.org", "summary": ""}